Sage Therapeutics Axes GC After Drug-Pipeline Failures Force Cost-Cutting

Sage is lopping off one-third of its workforce after one of its experimental drugs failed to prove effective as a treatment for Parkinson’s and Alzheimer’s.

       
News
Author: News

Comments

Leave a Reply

Your email address will not be published. Required fields are marked *